ClinicalTrials.gov
Cure8 trial brief
Alpha Lipoic Acid in Ulcerative Colitis
Research and clinical trials
Mesalamine
Aminosalicylates
Phase 2 clinical trial
Adult patients
Clinicians
Researchers
Patients On Biologics
Why This Matters
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate ulcerative colitis. If effective and safe, it could become an adjunctive option alongside 5-ASA therapy.
Who Should Pay Attention
Adults with mild-to-moderate ulcerative colitis, gastroenterologists and IBD clinicians, clinical researchers studying adjunctive or antioxidant therapies for IBD.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment60 participants
Study statusCompleted
Source depthTrial registry record
What To Know
This is a clinical trial record (completed) evaluating alpha-lipoic acid as an add-on to mesalamine versus placebo in adults with mild-to-moderate ulcerative colitis. The randomized interventional study planned enrollment of 60 participants at Tanta University Hospital (Egypt).
Interventions: mesalamine 1000 mg TID plus alpha-lipoic acid 600 mg once daily for 3 months, compared with mesalamine 1000 mg TID plus placebo. Primary outcomes included change in health-related quality of life (Short IBD Questionnaire) and change in disease severity (Partial Mayo Score) at 3 months.
Keep In Mind
This entry is a trial registry record (ClinicalTrials.gov) with planned interventions, eligibility, and endpoints. The record lists the study as completed but does not provide results here; consult the registry entry or published reports for outcomes and safety data before drawing conclusions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorTanta University
Trial IDNCT06067698
Study typeInterventional
Trial phaseNA
Enrollment60 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 29, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Dapagliflozin in Patients With Ulcerative Colitis
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
Treatment of UC With Novel Therapeutics
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...